Edition:
United States

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

14.43USD
25 May 2018
Change (% chg)

$0.28 (+1.98%)
Prev Close
$14.15
Open
$14.15
Day's High
$14.56
Day's Low
$14.05
Volume
195,195
Avg. Vol
305,142
52-wk High
$17.98
52-wk Low
$11.47

Chart for

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Overall

Beta: 2.06
Market Cap(Mil.): $1,464.21
Shares Outstanding(Mil.): 101.47
Dividend: --
Yield (%): --

Financials

  INVA.OQ Industry Sector
P/E (TTM): 11.63 29.19 33.30
EPS (TTM): 1.24 -- --
ROI: 45.94 13.53 13.04
ROE: -- 15.25 14.90

BRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive Officer

* INNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S

Apr 26 2018

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

Feb 13 2018

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

Feb 13 2018

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

Feb 12 2018

Drug company Innoviva settles with activist hedge fund Sarissa -sources

Feb 12 U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

Feb 12 2018

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 08 2018

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

Feb 07 2018

AstraZeneca's three-in-one inhaler helps COPD patients in trial

AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.

Jan 26 2018

UPDATE 1-AstraZeneca's 3-in-1 inhaler helps COPD patients in trial

Jan 26 AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.

Jan 26 2018

Earnings vs. Estimates